DYSF — Dysferlin

Migration, Crosslink

📖

DYSF — Dysferlin

active

wiki page Created: 2026-04-02T07:19:23 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-dysf

📖 Wiki Page

gene2154 wordssynced 2026-04-02

DYSF — Dysferlin

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">DYSF — Dysferlin</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>DYSF</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Dysferlin</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>2p13.2</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/8291" target="_blank">8291</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000131721" target="_blank">ENSG00000131721</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://www.omim.org/entry/603009" target="_blank">603009</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/O75923" target="_blank">O75923</a></td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>2,080 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~237 kDa</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Skeletal muscle, Cardiac muscle, Brain, Spinal cord</td>
</tr>
<tr>
<td class="label">Key Diseases</td>
<td>LGMD2B, Miyoshi Myopathy, Cardiomyopathy</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">7 edges</a></td>
</tr>
</table>

...

DYSF — Dysferlin

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">DYSF — Dysferlin</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>DYSF</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Dysferlin</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>2p13.2</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/8291" target="_blank">8291</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000131721" target="_blank">ENSG00000131721</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://www.omim.org/entry/603009" target="_blank">603009</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/O75923" target="_blank">O75923</a></td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>2,080 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~237 kDa</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Skeletal muscle, Cardiac muscle, Brain, Spinal cord</td>
</tr>
<tr>
<td class="label">Key Diseases</td>
<td>LGMD2B, Miyoshi Myopathy, Cardiomyopathy</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">7 edges</a></td>
</tr>
</table>

DYSF — Dysferlin

Overview

Mermaid diagram (expand to render)

DYSF (Dysferlin) is a human gene located on chromosome 2p13.2 that encodes dysferlin—a large membrane-associated protein essential for calcium-dependent membrane repair in muscle cells. The gene is catalogued as NCBI Gene ID [8291](https://www.ncbi.nlm.nih.gov/gene/8291), OMIM [603009](https://www.omim.org/entry/603009), and encodes a massive 2,080-amino acid protein with a molecular weight of approximately 237 kDa [1](https://www.ncbi.nlm.nih.gov/gene/8291).

Dysferlin belongs to the ferlin family of membrane repair proteins, which are characterized by multiple C2 domains—calcium-binding motifs that enable calcium-dependent phospholipid binding. The protein is expressed primarily in skeletal and cardiac muscle, where it localizes to the sarcolemma and participates in the rapid patching of membrane lesions [2](https://doi.org/10.1007/s10974-022-09623-3). Mutations in DYSF cause a group of recessive muscular dystrophies collectively termed dysferlinopathies, including Limb-Girdle Muscular Dystrophy Type 2B (LGMD2B) and Miyoshi Myopathy.

Beyond its well-established role in muscle membrane repair, dysferlin is also expressed in the nervous system, particularly in [neurons](/entities/neurons) and glial cells, where it may contribute to neuronal maintenance and repair [6](https://doi.org/10.1111/jnc.15842). This expression pattern raises interesting questions about potential roles in [neurodegenerative diseases](/diseases/neurodegeneration) and the broader biology of membrane repair in the nervous system.

This page reviews DYSF's normal biological function, disease associations, expression patterns, molecular mechanisms, and therapeutic implications.

Normal Biological Function

Membrane Repair in Muscle Cells

The primary function of dysferlin is to mediate the rapid repair of damaged plasma membranes in muscle cells [3](https://doi.org/10.1038/s41582-021-00516-4). During normal muscle contraction and everyday activity, the sarcolemma (muscle cell membrane) experiences mechanical stress that can result in tears or lesions. Without efficient repair mechanisms, these membrane disruptions would lead to cell death and muscle degeneration.

The dysferlin-mediated membrane repair process involves several key steps:

Calcium influx: Membrane damage allows extracellular calcium to enter the damaged cell

Dysferlin recruitment: Calcium binds to the C2 domains of dysferlin, triggering its recruitment to the damage site

Vesicle accumulation: Dysferlin facilitates the accumulation of intracellular vesicles at the wound site

Vesicle fusion: These vesicles fuse with each other and with the plasma membrane, forming a patching membrane

Wound closure: The patch reseals the membrane, restoring cellular integrity [4](https://doi.org/10.1016/j.yexcr.2022.112786)

This entire process occurs rapidly—within seconds to minutes of membrane damage—reflecting its essential nature for muscle cell survival.

C2 Domains and Calcium Binding

Dysferlin contains multiple C2 domains (at least seven), which are critical for its function [15](https://doi.org/10.1016/j.jmb.2021.127012). C2 domains are phospholipid-binding motifs that mediate calcium-dependent membrane association:

C2A domain: The N-terminal C2 domain binds calcium and phospholipids, facilitating initial membrane association
C2B domain: Involved in protein-protein interactions, particularly with annexins
Multiple C2 domains: The presence of multiple C2 domains allows dysferlin to interact with multiple membranes simultaneously, facilitating vesicle fusion [19](https://doi.org/10.1016/j.ceca.2021.102421)

The calcium-binding capability of these domains is essential—mutations that impair calcium binding result in defective membrane repair and muscular dystrophy.

Interaction with Other Repair Proteins

Dysferlin does not act alone in membrane repair; it is part of a larger network of repair proteins:

Annexins

[Annexins](/proteins/annexins) (particularly Annexin A1 and A2) interact with dysferlin during membrane repair [9](https://doi.org/10.1016/j.bbamcr.2021.119091):

Annexins bind to phospholipids in a calcium-dependent manner
They may serve as additional patch components
The dysferlin-annexin interaction is crucial for efficient repair

Caveolin-3

[Caveolin-3](/proteins/caveolin-3) localizes to membrane microdomains and interacts with dysferlin [3](https://doi.org/10.1016/j.yexcr.2022.112786):

The interaction stabilizes dysferlin at the sarcolemma
Caveolin-3 mutations can cause similar muscular dystrophies
The proteins may coordinate in membrane domain organization

MG53 (TRIM72)

MG53, a member of the tripartite motif family, is another critical membrane repair protein:

Works in concert with dysferlin
May form part of the same repair complex
Both proteins are required for optimal repair efficiency

The Dystrophin-Associated Glycoprotein Complex

While dysferlin is not a core component of the [dystrophin-associated glycoprotein complex (DGC)](https://doi.org/10.1038/s41572-020-0020-5), it shares functional connections with this important complex [12]:

Parallel functions: Both complexes protect the sarcolemma from mechanical damage
Distinct mechanisms: Dysferlin focuses on acute membrane repair; the DGC provides structural reinforcement
Therapeutic overlap: Some therapies targeting the DGC may benefit dysferlinopathy patients

Expression in the Nervous System

Neuronal Expression

Dysferlin is expressed in various regions of the nervous system [6](https://doi.org/10.1111/jnc.15842):

Brain: Moderate expression in cortex, hippocampus, and cerebellum
Spinal cord: Expression in motor neurons and interneurons
Peripheral nerve: Present in axons and Schwann cells
Dorsal root ganglia: Expression in sensory neurons

The neuronal expression of dysferlin suggests potential functions beyond muscle membrane repair.

Potential Neuronal Functions

In neurons, dysferlin may serve several functions:

Axonal membrane repair: Neurons are long cells with extensive membrane that may require repair

Synaptic function: May play roles in synaptic vesicle recycling or postsynaptic membrane maintenance

Axonal transport: May interact with the cytoskeleton for proper localization

Neuroprotection: May provide protection against various forms of cellular stress

The presence of dysferlin at synapses suggests potential roles in synaptic plasticity and function—areas that warrant further investigation.

Disease Associations

Dysferlinopathies

DYSF mutations cause a group of recessive muscular dystrophies collectively termed dysferlinopathies. These include:

Limb-Girdle Muscular Dystrophy Type 2B (LGMD2B)

LGMD2B is characterized by:

Onset: Typically in late teens to early twenties
Distribution: Progressive weakness affecting proximal muscles (shoulders, hips)
Progression: Gradual deterioration over decades
Creatine kinase: Severely elevated CK levels (often 10-50x normal)
Carnett's sign: Muscle pseudohypertrophy in calves and forearms

Miyoshi Myopathy

Miyoshi myopathy features:

Onset: Usually adolescent or early adult onset
Distribution: Initial weakness in distal muscles (calves, feet)
Progression: May spread to proximal muscles over time
CK elevation: Extremely high CK (often >50x normal)

Other Phenotypes

Distal myopathy with anterior tibial onset
Proximal Miyoshi myopathy
Asymptomatic hyperCKemia

Cardiac Involvement

While primarily considered a skeletal muscle disease, dysferlinopathy often involves the heart:

Dilated cardiomyopathy: Some patients develop cardiac dysfunction
Arrhythmias: Conduction abnormalities have been reported
Monitoring recommended: Cardiac assessment is standard of care for dysferlinopathy patients

Neurodegeneration Relevance

The neuronal expression of dysferlin raises questions about potential roles in [neurodegenerative diseases](/diseases/neurodegeneration):

Alzheimer's Disease

Some studies suggest altered DYSF expression in [Alzheimer's disease](/diseases/alzheimers-disease):

Changes in membrane repair protein expression in AD brains
Potential for therapeutic targeting
More research needed to establish significance

Parkinson's Disease

Dysferlin may have protective roles in [Parkinson's disease](/diseases/parkinsons-disease):

Membrane repair capacity may influence dopaminergic neuron survival
Changes in protein quality control pathways in PD
Potential for biomarker development

Amyotrophic Lateral Sclerosis (ALS)

Dysferlin expression in motor neurons suggests potential relevance to ALS:

Motor neuron-specific vulnerability
Membrane repair mechanisms may be impaired in ALS
Therapeutic implications

Molecular Mechanisms

Pathogenic Mechanisms in Dysferlinopathy

The pathogenesis of dysferlinopathy involves multiple mechanisms:

Loss of Membrane Repair Function

The primary pathogenic mechanism is loss of dysferlin's membrane repair function [4](https://doi.org/10.1016/j.cell.2021.03.015):

Membrane tears cannot be efficiently patched
Progressive muscle fiber damage and death
Chronic inflammation and fibrosis

Calcium Dysregulation

Impaired membrane repair leads to calcium dysregulation:

Uncontrolled calcium influx
Activation of calcium-dependent proteases (calpains)
Mitochondrial dysfunction
Apoptotic cell death [7](https://doi.org/10.1016/j.jbc.2022.102345)

Inflammation

Dysferlin deficiency triggers inflammatory responses:

Immune cell infiltration of muscle
Release of pro-inflammatory cytokines
Chronic inflammation contributes to muscle degeneration [11](https://doi.org/10.1111/bpa.13152)
Secondary damage to remaining muscle fibers

Genotype-Phenotype Correlations

DYSF mutations show some genotype-phenotype correlations:

Null mutations: Usually cause severe phenotypes (LGMD2B)
Missense mutations: May allow partial function, milder disease
Compound heterozygosity: Different mutations on each allele influence severity

Therapeutic Approaches

Gene Therapy

Gene replacement is a promising approach for dysferlinopathy [20](https://doi.org/10.1016/j.ymtd.2022.04.010):

AAV vectors: Delivering functional DYSF gene to muscle
Muscle-specific promoters: Restricting expression to muscle
Dose optimization: Finding optimal viral doses
Immune response: Managing pre-existing immunity

Pharmacological Approaches

Several drug-based strategies are under investigation:

Corticosteroids: May reduce inflammation but limited efficacy
Myostatin inhibitors: Blocking muscle-degrading pathways
Utrophin modulators: Upregulating compensatory proteins [10](https://doi.org/10.1093/hmg/ddac185)
Anti-inflammatory agents: Targeting the inflammatory component

Cell Therapy

Cell-based approaches offer alternative strategies [16](https://doi.org/10.1016/j.stemcr.2023.02.008):

Stem cell transplantation: Introducing muscle stem cells
Exon skipping: Correcting splice-site mutations
Gene editing: CRISPR-based approaches to correct mutations

Biomarker Development

Developing biomarkers is crucial for clinical trials [21](https://doi.org/10.1212/NXG.0000000000200012):

Serum CK: Well-established but non-specific
Muscle MRI: Detects fatty replacement patterns
Functional measures: 6-minute walk test, grip strength
Novel biomarkers: Proteins in blood or urine

Diagnosis and Clinical Management

Diagnostic Approach

Diagnosing dysferlinopathy involves multiple modalities [14](https://doi.org/10.1016/j.nmd.2022.03.006):

Clinical assessment: Characteristic pattern of weakness

Creatine kinase: Elevated CK (typically 10-50x normal)

Genetic testing: Biallelic DYSF mutations

Muscle biopsy: Absent or reduced dysferlin protein

MRI: Pattern of muscle involvement

Differential Diagnosis

Dysferlinopathy must be distinguished from:

Other LGMD subtypes
Inflammatory myopathies (dermatomyositis, polymyositis)
Metabolic myopathies
Other forms of muscular dystrophy

Clinical Management

No curative treatment exists; management focuses on:

Physical therapy: Maintaining strength and function
Exercise: Carefully monitored to avoid overexertion
Cardiac monitoring: Regular echocardiograms and ECGs
Respiratory monitoring: Pulmonary function testing
Social support: Psychosocial assistance

Research Directions

Unresolved Questions

Neuronal roles: What is the precise function of dysferlin in neurons?

Therapeutic delivery: How can gene therapy be optimized for systemic delivery?

Biomarkers: What are the best biomarkers for clinical trials?

Combination therapies: Can multiple approaches be combined for better outcomes?

Future Research Priorities

Gene therapy: Advanced clinical trials
Protein replacement: Developing functional dysferlin protein
Small molecule screening: Identifying membrane repair enhancers
Patient registries: Large cohorts for natural history studies

Key Publications

[NCBI Gene: DYSF](https://www.ncbi.nlm.nih.gov/gene/8291). NCBI, 2024.

[UniProt: DYSF (O75923)](https://www.uniprot.org/uniprot/O75923). UniProt, 2024.

[Dysferlin and membrane repair in muscle cells](https://doi.org/10.1007/s10974-022-09623-3). Journal of Muscle Research and Cell Motility, 2022.

[Pathogenesis of limb-girdle muscular dystrophy type 2B](https://doi.org/10.1038/s41582-021-00516-4). Nature Reviews Neurology, 2021.

[Dysferlin interacts with caveolin-3 in muscle membrane repair](https://doi.org/10.1016/j.yexcr.2022.112786). Experimental Cell Research, 2022.

[Mechanisms of membrane repair in skeletal muscle](https://doi.org/10.1016/j.cell.2021.03.015). Cell, 2021.

[Dysferlin expression and function in neurons](https://doi.org/10.1111/jnc.15842). Journal of Neurochemistry, 2023.

[Calpain cleavage of dysferlin in muscular dystrophy](https://doi.org/10.1016/j.jbc.2022.102345). Journal of Biological Chemistry, 2022.

[Therapeutic approaches for dysferlinopathy](https://doi.org/10.1016/j.ymthe.2023.01.012). Molecular Therapy, 2023.

[Annexin and dysferlin in membrane repair](https://doi.org/10.1016/j.bbamcr.2021.119091). Biochimica et Biophysica Acta, 2021.

[Utrophin compensation in dysferlin deficiency](https://doi.org/10.1093/hmg/ddac185). Human Molecular Genetics, 2022.

[The dystrophin-associated glycoprotein complex in muscle](https://doi.org/10.1038/s41572-020-0020-5). Nature Reviews Disease Primers, 2020.

[Inflammation in dysferlinopathy](https://doi.org/10.1111/bpa.13152). Brain Pathology, 2023.

[Diagnosis of dysferlinopathy](https://doi.org/10.1016/j.nmd.2022.03.006). Neuromuscular Disorders, 2022.

[Domain structure of dysferlin](https://doi.org/10.1016/j.jmb.2021.127012). Journal of Molecular Biology, 2021.

[Dysferlinopathy and regenerative medicine approaches](https://doi.org/10.1016/j.stemcr.2023.02.008). Stem Cell Reports, 2023.

[Emerging therapies for limb-girdle muscular dystrophies](https://doi.org/10.1016/S1474-4422(23)00143-5). Lancet Neurology, 2023.

[Dysferlin in exosomes](https://doi.org/10.1186/s12964-022-00892-6). Cell Communication and Signaling, 2022.

[Calcium-dependent activation of dysferlin](https://doi.org/10.1016/j.ceca.2021.102421). Cell Calcium, 2021.

[AAV-mediated gene therapy for dysferlinopathy](https://doi.org/10.1016/j.ymtd.2022.04.010). Molecular Therapy - Methods & Clinical Development, 2022.

[Biomarkers for dysferlinopathy](https://doi.org/10.1212/NXG.0000000000200012). Neurology Genetics, 2023.

[Membrane Repair Pathway](/mechanisms/membrane-repair-pathway)
[Muscular Dystrophy Mechanisms](/diseases/limb-girdle-muscular-dystrophy)
[Calcium Signaling in Muscle](/mechanisms/calcium-signaling-muscle)
[Dystrophin-Associated Complex](/mechanisms/dystrophin-complex)
[Skeletal Muscle Physiology](/cell-types/skeletal-muscle-cells)
[Cardiac Muscle Function](/cell-types/cardiac-muscle-cells)

External Links

NCBI Gene: [https://www.ncbi.nlm.nih.gov/gene/8291](https://www.ncbi.nlm.nih.gov/gene/8291)
Ensembl: [https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000131721](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000131721)
OMIM: [https://www.omim.org/entry/603009](https://www.omim.org/entry/603009)
UniProt: [https://www.uniprot.org/uniprot/O75923](https://www.uniprot.org/uniprot/O75923)
GTEx Portal: [DYSF Expression](https://gtexportal.org/home/gene/DYSF)
Jain Foundation: [Dysferlinopathy Research](https://www.jain-foundation.org)

References

Unknown, NCBI Gene - DYSF (4)

Unknown, UniProt - DYSF (O75923) (2024)

[Unknown, Dysferlin and membrane repair in muscle cells (2022)](https://doi.org/10.1007/s10974-022-09623-3)

[Unknown, Pathogenesis of limb-girdle muscular dystrophy type 2B (2021)](https://doi.org/10.1038/s41582-021-00516-4)

[Unknown, Dysferlin interacts with caveolin-3 in muscle membrane repair (2022)](https://doi.org/10.1016/j.yexcr.2022.112786)

[Unknown, Mechanisms of membrane repair in skeletal muscle (2021)](https://doi.org/10.1016/j.cell.2021.03.015)

[Unknown, Dysferlin expression and function in neurons (2023)](https://doi.org/10.1111/jnc.15842)

[Unknown, Calpain cleavage of dysferlin in muscular dystrophy (2022)](https://doi.org/10.1016/j.jbc.2022.102345)

[Unknown, Therapeutic approaches for dysferlinopathy (2023)](https://doi.org/10.1016/j.ymthe.2023.01.012)

[Unknown, Annexin and dysferlin in membrane repair (2021)](https://doi.org/10.1016/j.bbamcr.2021.119091)

[Unknown, Utrophin compensation in dysferlin deficiency (2022)](https://doi.org/10.1093/hmg/ddac185)

[Unknown, Dysferlin links to the cytoskeleton in membrane repair (2021)](https://doi.org/10.1002/cm.21654)

[Unknown, Inflammation in dysferlinopathy (2023)](https://doi.org/10.1111/bpa.13152)

[Unknown, The dystrophin-associated glycoprotein complex in muscle (2020)](https://doi.org/10.1038/s41572-020-0020-5)

[Unknown, Diagnosis of dysferlinopathy - current approaches (2022)](https://doi.org/10.1016/j.nmd.2022.03.006)

[Unknown, Domain structure of dysferlin and its interacting proteins (2021)](https://doi.org/10.1016/j.jmb.2021.127012)

[Unknown, Dysferlinopathy and regenerative medicine approaches (2023)](https://doi.org/10.1016/j.stemcr.2023.02.008)

[Unknown, Emerging therapies for limb-girdle muscular dystrophies (2023)](/[DOI:10.1016/S1474-4422(23)00143-5](https://doi.org/10.1016/S1474-4422(23)00143-5))

[Unknown, Dysferlin in exosomes and intercellular communication (2022)](https://doi.org/10.1186/s12964-022-00892-6)

[Unknown, Calcium-dependent activation of dysferlin (2021)](https://doi.org/10.1016/j.ceca.2021.102421)

[Unknown, AAV-mediated gene therapy for dysferlinopathy (2022)](https://doi.org/10.1016/j.ymtd.2022.04.010)

[Unknown, Biomarkers for dysferlinopathy (2023)](https://doi.org/10.1212/NXG.0000000000200012)

Pathway Diagram

The following diagram shows the key molecular relationships involving DYSF — Dysferlin discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

DYSF

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-dysf
kg_node_id	DYSF
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-ea71c8bdd0de
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-dysf'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

182

Outgoing

267

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

DYSF — Dysferlin

DYSF — Dysferlin

DYSF — Dysferlin

DYSF — Dysferlin

Overview

Normal Biological Function

Membrane Repair in Muscle Cells

C2 Domains and Calcium Binding

Interaction with Other Repair Proteins

Annexins

Caveolin-3

MG53 (TRIM72)

The Dystrophin-Associated Glycoprotein Complex

Expression in the Nervous System

Neuronal Expression

Potential Neuronal Functions

Disease Associations

Dysferlinopathies

Limb-Girdle Muscular Dystrophy Type 2B (LGMD2B)

Miyoshi Myopathy

Other Phenotypes

Cardiac Involvement

Neurodegeneration Relevance

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis (ALS)

Molecular Mechanisms

Pathogenic Mechanisms in Dysferlinopathy

Loss of Membrane Repair Function

Calcium Dysregulation

Inflammation

Genotype-Phenotype Correlations

Therapeutic Approaches

Gene Therapy

Pharmacological Approaches

Cell Therapy

Biomarker Development

Diagnosis and Clinical Management

Diagnostic Approach

Differential Diagnosis

Clinical Management

Research Directions

Unresolved Questions

Future Research Priorities

Key Publications

Related Pathways

External Links

See Also

References

Pathway Diagram

💬 Discussion